MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.

Neuroinflammation is critical in the neural cell death seen in stroke. It has been shown that CNS and peripheral responses drive this neuroinflammatory response in the brain. The Toll-like receptors (TLRs) are important regulators of inflammation in response to both exogenous and endogenous stressor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Catherine E Downes, Connie H Y Wong, Katya J Henley, Pedro L Guio-Aguilar, Moses Zhang, Robert Ates, Ashley Mansell, Benjamin T Kile, Peter J Crack
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aba7a1673b1c4d669cd0e9194af99a57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aba7a1673b1c4d669cd0e9194af99a57
record_format	dspace
spelling	oai:doaj.org-article:aba7a1673b1c4d669cd0e9194af99a572021-11-18T07:55:03ZMyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.1932-620310.1371/journal.pone.0057948https://doaj.org/article/aba7a1673b1c4d669cd0e9194af99a572013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23483951/?tool=EBIhttps://doaj.org/toc/1932-6203Neuroinflammation is critical in the neural cell death seen in stroke. It has been shown that CNS and peripheral responses drive this neuroinflammatory response in the brain. The Toll-like receptors (TLRs) are important regulators of inflammation in response to both exogenous and endogenous stressors. Taking advantage of a downstream adapter molecule that controls the majority of TLR signalling, this study investigated the role of the TLR adaptor protein myeloid differentiation factor 88 (MyD88) in the control of CNS and peripheral inflammation. Reversible middle-cerebral artery occlusion was used as the model of stroke in vivo; in vitro primary cultured neurons and glia were subject to four hours of oxygen and glucose deprivation (OGD). Both in vitro and in vivo Myd88(-/-) animals or cells were compared with wild type (WT). We found that after stroke Myd88(-/-) animals have a larger infarct volume compared to WT animals. Interestingly, in vitro there was no difference between the survival of Myd88(-/-) and WT cells following OGD, suggesting that peripheral responses were influencing stroke outcome. We therefore generated bone marrow chimeras and found that Myd88(-/-) animals have a smaller stroke infarct than their radiation naive counterparts if their hematopoietic cells are WT. Furthermore, WT animals have a larger stroke than their radiation naive counterparts if the hematopoietic cells are Myd88(-/-) . We have demonstrated that MyD88-dependent signalling in the hematopoietic cell lineage reduces infarct size following stroke and that infiltrating cells to the site of neuroinflammation are neuroprotective following stroke.Catherine E DownesConnie H Y WongKatya J HenleyPedro L Guio-AguilarMoses ZhangRobert AtesAshley MansellBenjamin T KilePeter J CrackPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e57948 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Catherine E Downes Connie H Y Wong Katya J Henley Pedro L Guio-Aguilar Moses Zhang Robert Ates Ashley Mansell Benjamin T Kile Peter J Crack MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
description	Neuroinflammation is critical in the neural cell death seen in stroke. It has been shown that CNS and peripheral responses drive this neuroinflammatory response in the brain. The Toll-like receptors (TLRs) are important regulators of inflammation in response to both exogenous and endogenous stressors. Taking advantage of a downstream adapter molecule that controls the majority of TLR signalling, this study investigated the role of the TLR adaptor protein myeloid differentiation factor 88 (MyD88) in the control of CNS and peripheral inflammation. Reversible middle-cerebral artery occlusion was used as the model of stroke in vivo; in vitro primary cultured neurons and glia were subject to four hours of oxygen and glucose deprivation (OGD). Both in vitro and in vivo Myd88(-/-) animals or cells were compared with wild type (WT). We found that after stroke Myd88(-/-) animals have a larger infarct volume compared to WT animals. Interestingly, in vitro there was no difference between the survival of Myd88(-/-) and WT cells following OGD, suggesting that peripheral responses were influencing stroke outcome. We therefore generated bone marrow chimeras and found that Myd88(-/-) animals have a smaller stroke infarct than their radiation naive counterparts if their hematopoietic cells are WT. Furthermore, WT animals have a larger stroke than their radiation naive counterparts if the hematopoietic cells are Myd88(-/-) . We have demonstrated that MyD88-dependent signalling in the hematopoietic cell lineage reduces infarct size following stroke and that infiltrating cells to the site of neuroinflammation are neuroprotective following stroke.
format	article
author	Catherine E Downes Connie H Y Wong Katya J Henley Pedro L Guio-Aguilar Moses Zhang Robert Ates Ashley Mansell Benjamin T Kile Peter J Crack
author_facet	Catherine E Downes Connie H Y Wong Katya J Henley Pedro L Guio-Aguilar Moses Zhang Robert Ates Ashley Mansell Benjamin T Kile Peter J Crack
author_sort	Catherine E Downes
title	MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
title_short	MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
title_full	MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
title_fullStr	MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
title_full_unstemmed	MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
title_sort	myd88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/aba7a1673b1c4d669cd0e9194af99a57
work_keys_str_mv	AT catherineedownes myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT conniehywong myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT katyajhenley myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT pedrolguioaguilar myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT moseszhang myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT robertates myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT ashleymansell myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT benjamintkile myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke AT peterjcrack myd88isacriticalregulatorofhematopoieticcellmediatedneuroprotectionseenafterstroke
_version_	1718422749945266176

MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.

Ejemplares similares